Sodium Phenylacetate and Sodium Benzoate

Drug class: Antineoplastic Agents

Usage of Sodium Phenylacetate and Sodium Benzoate

Acute Hyperammonemia

Adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with urea cycle disorders (e.g., deficiency in carbamyl phosphate synthetase [CPS], ornithine transcarbamylase [OTC], argininosuccinate synthetase [ASS], or argininosuccinate lyase [ASL]); designated an orphan drug by FDA for this use.

Treat any episode of acute symptomatic hyperammonemia as a life-threatening emergency; prompt use of all necessary therapies (e.g., dialysis [preferably hemodialysis], caloric supplementation, protein restriction) to reduce ammonia concentrations is essential.

Hemodialysis is the preferred therapy for acute neonatal hyperammonemic coma, moderate to severe episodes of hyperammonemic encephalopathy, and episodes of hyperammonemia that fail to respond to an initial course of sodium phenylacetate and sodium benzoate therapy. In such patients, administration of sodium phenylacetate and sodium benzoate helps prevent reaccumulation of ammonia by increasing waste nitrogen excretion.

Concomitant therapy with IV arginine hydrochloride is required in patients with CPS, OTC, ASS, or ASL deficiency; however, IV arginine hydrochloride is contraindicated in patients with arginase deficiency. Pending specific diagnosis, also give IV arginine hydrochloride to hyperammonemic infants with suspected urea cycle disorders.

If a urea cycle disorder is suspected based on family history, document hyperammonemia before administering sodium phenylacetate and sodium benzoate.

Relate drugs

How to use Sodium Phenylacetate and Sodium Benzoate

General

  • Initiate therapy immediately following the diagnosis of hyperammonemia.
  • Prior to infusion, discontinue analogous oral agents (e.g., sodium phenylbutyrate).
  • May administer an antiemetic during the infusion for management of possible nausea and vomiting.
  • Start or resume oral therapy (e.g., sodium phenylbutyrate), dietary management, and protein restriction when ammonia concentrations reduced to the normal range.
  • Dialysis is recommended for those patients who do not have a significant reduction in plasma ammonia levels within 4–8 hours after receiving sodium phenylacetate and sodium benzoate.
  • Concomitant therapy with arginine hydrochloride may be required. Consult the prescribing information for arginine hydrochloride for complete dosing and other information.

    • Administration

    IV Administration

    For solution and drug compatibility information, see Compatibility under Stability.

    Administer by IV infusion through a central venous line only; administration through a peripheral line may cause burns.

    Vials are for single use only.

    Dilution

    Mustbe diluted in 10% dextrose injection prior to administration.

    Always use the Millex Durapore GV 33-mm sterile syringe filter (0.22 µm) provided by the manufacturer when diluting sodium phenylacetate and sodium benzoate injection regardless of whether particulate matter is visible in the vial. Particulate matter has been reported but may notbe readily observed on visual inspection; removal of these particulates by this filter has been confirmed. (See Detection of Particulate Matter in Commercial Preparations under Cautions.)

    Prepare IV infusion in glass or PVC container.

    Determine the volume of diluent based on the patient’s weight (neonates, infants, and children weighing ≤20 kg) or BSA (children weighing >20 kg, adolescents, and adults). Dilute each loading or maintenance dose of injection concentrate in ≥25 mL/kg of body weight of 10% dextrose injection.

    Rate of Administration

    Administer loading dose over 90–120 minutes.

    Administer maintenance dose over 24 hours.

    Dosage

    Available as sodium phenylacetate and sodium benzoate; dosage expressed in terms of the salts.

    Base dosages in neonates, infants, and children weighing ≤20 kg on body weight; base dosages in pediatric patients weighing >20 kg and in adults on body surface area.

    Pediatric Patients

    Acute Hyperammonemia IV

    Pediatric patients weighing ≤20 kg: Loading dose of 250 mg/kg sodium phenylacetate in fixed combination with 250 mg/kg sodium benzoate infused over 90–120 minutes. Maintenance dose of 250 mg/kg of sodium phenylacetate and 250 mg/kg sodium benzoate infused over 24 hours.

    Pediatric patients weighing >20 kg: Loading dose of 5.5 g/m2 sodium phenylacetate and 5.5 g/m2 sodium benzoate infused over 90–120 minutes. Maintenance dose of 5.5 g/m2 sodium phenylacetate and 5.5 g/m2 of sodium benzoate infused over 24 hours.

    Continue maintenance infusions until elevated plasma ammonia concentrations decrease to normal levels or until patient can tolerate oral nutrition and drug therapy.

    Repeat Loading Doses IV

    Manufacturer states do not repeat loading doses; however, some experts state that a repeat loading dose within 24 hours should be considered only in neonates with severe disorders and/or those receiving dialysis; space loading doses ≥6 hours apart. (See Laboratory Monitoring and also see Repeat Loading Doses under Cautions.)

    Adults

    Acute Hyperammonemia IV

    Loading dose: 5.5 g/m2 sodium phenylacetate and 5.5 g/m2 sodium benzoate infused over 90–120 minutes. Manufacturer states do not repeat loading doses.

    Maintenance dose: 5.5 g/m2 sodium phenylacetate and 5.5 g/m2 sodium benzoate infused over 24 hours.

    Continue maintenance infusions until elevated plasma ammonia concentrations decrease to normal levels or until patient can tolerate oral nutrition and drug therapy.

    Special Populations

    No special population dosage recommendations at this time. (See Hepatic Impairment and see Renal Impairment under Cautions and also see Special Populations under Pharmacokinetics.)

    Warnings

    Contraindications

  • Known hypersensitivity to sodium phenylacetate or sodium benzoate or any ingredient in the formulation.

    • Warnings/Precautions

    Warnings

    Emergency Treatment of Hyperammonemia

    Risk of rapid brain damage or death if acute symptomatic hyperammonemia is left uncontrolled; treat as a life-threatening emergency. Prompt use of all therapies to reduce serum ammonia concentrations (e.g., dialysis [preferably hemodialysis]) is essential. (See Acute Hyperammonemia under Uses.)

    Manage hyperammonemia due to inborn errors of metabolism in coordination with medical personnel familiar with such conditions; usually requires health-care facilities able to provide multidisciplinary treatment (e.g., hemodialysis, nutritional management, medical support).

    Laboratory Monitoring

    Closely monitor plasma ammonia concentrations, neurologic status, laboratory tests, and clinical response during treatment.

    Monitor serum electrolyte concentrations; maintain within the normal range.

    Urinary loss of potassium is enhanced by excretion of nonabsorbable anions phenylacetylglutamine and hippurate; carefully monitor plasma potassium concentrations and provide replacement therapy, when necessary.

    Perform blood chemistry profiles and frequent blood pH and blood gases (e.g., pCO2) evaluations to check for salicylate-like toxicity. (See Salicylate-like Toxicity under Cautions.)

    The Urea Cycle Disorders Conference Group and some experts recommend monitoring plasma concentrations of ammonia scavenging drugs (e.g., sodium phenylacetate and sodium benzoate) to avoid toxicity. Weigh the risk of overdosage against potential benefits of repeating a loading dose in the absence of facilities for drug concentration monitoring. (See Repeat Loading Doses under Dosage and Administration and also see Repeat Loading Doses under Cautions.)

    Possible Prescribing Errors

    Experts recommend double-checking the accuracy of prescription orders to avoid possible overdosage.

    Detection of Particulate Matter in Commercial Preparations

    Particulate matter has been detected in sodium phenylacetate and sodium benzoate injections. Particulates may notbe readily observed on visual inspection. Because these particulates could potentially affect injection safety, always use the Millex Durapore GV 33-mm sterile syringe filter (0.22 µm) provided by the manufacturer when diluting the injection (see Dilution under Dosage and Administration). Removal of these particulates by this filter has been confirmed.

    Report any quality problems or suspected adverse effects to the manufacturer (800-900-6389) or the FDA MedWatch program.

    For addditional information, see [Web] or [Web].

    Extravasation

    Do not administer injection concentrate undiluted; only administer via a central line. Peripheral venous administration may cause burns.

    Extravasation into perivenous tissue may lead to skin necrosis. Carefully monitor the infusion site during infusion. If extravasation is suspected, discontinue the infusion and resume at a different site, if necessary. Treatment for extravasation may include aspiration of residual drug from the catheter, limb elevation, and intermittent cooling with cold packs.

    Sodium Content

    Each g of sodium phenylacetate provides 6.3 mEq (145 mg) of sodium, and each g of sodium benzoate provides 7 mEq (160 mg) of sodium; each mL of injection concentrate labeled as containing 100 mg each of sodium phenylacetate and sodium benzoate provides 1.33 mEq (30.5 mg) of sodium.

    Consider sodium content and use with caution, if at all, in patients with CHF, severe renal impairment, or sodium retention with edema. If adverse effects associated with increased sodium concentrations occur, discontinue the drug, promptly evaluate the patient, and take appropriate measures.

    Salicylate-like Toxicity

    Structurally similar to salicylate; possibility of adverse effects (e.g., hyperventilation, metabolic acidosis) typically associated with acute salicylate toxicity. (See Laboratory Monitoring under Cautions.)

    Major Toxicities

    Neurotoxicity

    Adverse neurotoxic effects (e.g., somnolence, fatigue, lightheadedness, headache, dysgeusia, hypoacusis, disorientation, impaired memory, exacerbation of existing neuropathy) reported in cancer patients receiving IV phenylacetate. Acute onset (mainly mild) occurred upon initiation of therapy; reversible upon discontinuance of the drug.

    General Precautions

    Repeat Loading Doses

    The manufacturer states that, because plasma concentrations of phenylacetate are prolonged, do not repeat loading doses. However, some experts state that a repeat loading dose within 24 hours should be considered only in neonates with severe disorders and/or those receiving dialysis; space loading doses at least 6 hours apart. (See Repeat Loading Doses under Dosage and Administration and see Laboratory Monitoring under Cautions.)

    Hyperbilirubinemia

    Risk of indirect hyperbilirubinemia. Use with caution in neonates with hyperbilirubinemia. In infants at risk, reduce serum bilirubin concentrations to normal range before initiating therapy with sodium phenylacetate and sodium benzoate.

    Dialysis

    Manufacturer states drug is complementary with dialysis (e.g., standard hemodialysis, peritoneal dialysis, arteriovenous hemofiltration).

    Specific Populations

    Pregnancy

    Category C.

    Lactation

    Not known whether sodium phenylacetate or sodium benzoate or their conjugated metabolites are distributed into milk. Use with caution in nursing women.

    Pediatric Use

    Efficacy is established for treatment of hyperammonemia in pediatric patients 0–16 years of age, including neonates (0–30 days of age) and infants (31 days–2 years of age).

    Use with caution in neonates with hyperbilirubinemia. (See Hyperbilirubinemia under Cautions.)

    Hepatic Impairment

    Use with caution in patients with hepatic impairment. (See Metabolism under Pharmacokinetics.)

    Renal Impairment

    Use with caution and carefully monitor patients with renal impairment. (See Elimination under Pharmacokinetics.)

    Common Adverse Effects

    Vomiting, hyperglycemia, hypokalemia, seizures, mental impairment.

    What other drugs will affect Sodium Phenylacetate and Sodium Benzoate

    No formal drug interaction studies to date.

    Specific Drugs

    Drug

    Interaction

    Anti-infective agents (e.g., penicillin)

    Some anti-infective agents may compete with phenylacetylglutamine and hippurate for active renal tubular secretion, affecting drug disposition

    Corticosteroids

    Corticosteroids may increase plasma ammonia concentrations by causing protein catabolism

    Probenecid

    Probenecid inhibits renal transport of organic compounds (including aminohippuric acid)

    Probenecid may affect renal excretion of phenylacetylglutamine and hippurate

    Valproic acid

    Valproic acid may induce hyperammonemia via inhibition of N-acetylglutamate, a co-factor for carbamyl phosphate synthetase

    Concomitant use may exacerbate urea cycle disorders and antagonize plasma ammonia-lowering effects of the ammonia detoxicant

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords